Notably, STAT3 is an emergent target anti-cancer therapy [31], and data have indicated that STAT3 inhibition in immune cells may reprogram these cells to a tumoricidal phenotype, reduce tumor cell proliferation, angiogenesis, and metastasis [32,33]. The gene discussed is STAT3; the disease is neoplasm.